Anti-Human Carbonate dehydratase IX (CAIX) (Girentuximab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Girentuximab. Girentuximab specifically targets and binds to CAIX.

Carbonic anhydrase IX (CAIX) is a type of transmembrane metalloenzyme that has a significant role in maintaining the pH balance within cells. It is predominantly found in the gastrointestinal tract and gallbladder, where it facilitates acid secretion. In various types of cancer, such as clear cell renal cell carcinoma (ccRCC), and breast, lung, and cervical cancers, CAIX is often overexpressed in response to low oxygen levels (hypoxia) and is linked to a poor prognosis. CAIX contributes to the acidification of the surrounding environment, thereby promoting the growth and spread of tumors^1-3.

Girentuximab, also known as Rencarex, is a type of chimeric IgG1 monoclonal antibody that is designed to target CAIX3. Researchers have been studying its potential in treating renal cell carcinoma (RCC) because it effectively targets CAIX, which is typically found in high levels in most RCC cells. Girentuximab functions by initiating antibody-dependent cellular cytotoxicity (ADCC), destroying tumor cells that express CAIX. Despite the discontinuation of its development as a standalone antibody during phase III trials, scientists are still examining its use as a radioimmunoconjugate for both diagnostic and therapeutic applications^4,5.

CAIX is primarily expressed in the gastrointestinal tract and gallbladder. Its expression is significantly upregulated in various solid tumors, particularly in hypoxic environments.

Carbon dioxide

1. McDonald PC, Dedhar S. Subcell Biochem. 2014;75:255-269.
2. John A, Sivashanmugam M, Natarajan SK, Umashankar V. J Biomol Struct Dyn. 2020;38(7):1995-2006.
3. Choschzick M, Woelber L, Hess S, et al. Virchows Arch. 2010;456(5):483-490.
4. Muselaers CHJ, Boers-Sonderen MJ, van Oostenbrugge TJ, et al. Eur Urol. 2016;69(5):767-770.
5. Zatovicova M, Jelenska L, Hulikova A, et al. Int J Oncol. 2014;45(6):2455-2467.
6. Girentuximab Overview - Creative Biolabs. Accessed August 15, 2024. https://www.creativebiolabs.net/girentuximab-overview.htm?gclid=Cj0KCQjwzva1BhD3ARIsADQuPnXnAYWy3vGompPNowNBCoWbRrzTxgMjMZ-_SqLl1_wCX_5YaQfDRPwaAhNYEALw_wcB
7. Anti-CA9 Antibody (girentuximab biosimilar) (WX-G250), 12-9100. Accessed August 15, 2024. https://www.abeomics.com/anti-ca9-antibody-girentuximab-biosimilar-wx-g250